Prothena col­lects $60M Parkin­son's mile­stone from Roche; As­traZeneca's Pas­cal So­ri­ot faces proxy push­back on pay pack­age

Work­ing on a Parkin­son’s treat­ment in a col­lab­o­ra­tion with Roche, Prothena has col­lect­ed its lat­est mile­stone in pur­suit of that end goal.

The biotech se­cured a $60 mil­lion pay­ment from Roche for dos­ing the first pa­tient in a Phase IIb study eval­u­at­ing prasinezum­ab for the neu­ro­log­i­cal dis­ease, Prothena an­nounced Mon­day af­ter­noon. The new cash comes af­ter Prothena had al­ready col­lect­ed $75 mil­lion as part of its team-up with the big phar­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER